Seven pharma CEOs unite to achieve emission targets
In a global first, the health sector has converged to incentivise supply chains and clinical trials to reduce emissions through the Sustainable Markets Initiative Health Systems Task Force.
List view / Grid view
News
Global pharma confidence highest on record, shows CPhI Pharma Index
CPhI’s 2022 Pharma Index survey showed growth and quality scores improved considerably for every market, with India being the overall winner.
Live from CPhI: ‘Gut microbiome therapy to be approved in the next two years’
The promise of microbiome-based therapeutics is rapidly progressing towards real world applications as treatment of recurrent Clostridium difficile using faecal microbiota transplant edges towards a BLA.
Could GSK offer the first RSV older adult vaccine?
The EMA has accepted a marketing application for an RSV vaccine intended for older adults, the first potential vaccine for this age group with lower respiratory tract disease.
$8 million grant awarded to new US stem cell clinic
New US stem cell clinics given an $8 million grant will boost industry collaboration and advance regenerative medicine research, clinical trials and pioneering training.
“Universal” CRISPR-edited T cells improve resistant leukaemia
Children with leukaemia were successfully treated with first-in-human "universal" CRISPR-edited T-cells, by researchers at Great Ormond Street Hospital and University College London.
UK £62 billion behind in R&D global investment share, report reveals
The IPPR urges the UK government to increase R&D funding to strengthen economic growth and restore the UK’s leading global position.
Microneedle patches designed by AI restore hair in balding mice
Using AI, researchers have produced a nanozyme treatment for regenerating hair in mice, delivered via a microneedle.
New therapy for anaemic myelodysplastic cancer patients
Reblozyl, the first erythroid maturation agent showed increased haemoglobin in transfusion-dependant patients with myelodysplastic syndromes.
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
Janus kinase inhibitors used for chronic inflammatory conditions are only safe for certain patients, advises the EMA’s safety committee.
CPHI report predicts huge funding overhang to drive contract services growth
Private equity overhang to fuel CDMO valuations and expansions, while venture capital overhang will fuel continued demand for services in spite of adverse global conditions.
Biopharma successful in achieving climate-related goals, report finds
A report shows two Big Pharma companies made the top 10 in the FTSE sustainability leaderboard, yet progress against climate goals has stalled since COP26.
EMA’s PRAC confirms recommendation to withdraw amfepramones
The EMA’s safety board verifies that amfepramone-containing products for obesity should not be sold, due to higher-associated health risks.
EMA validates AbbVie lymphoma bispecific antibody application
AbbVie's marketing application for epcoritamab in adults with relapsed/refractory diffuse large B-cell lymphoma has been validated by the European Medicines Agency.
Outsourcing APIs put EU patients at risk
Teva warns APIs could disappear from European factories in five to 10 years if the industry does not see outsourcing essential medicine manufacture as risky.
